Newsroom

TAIPEI, Taiwan--(BUSINESS WIRE)--PharmaEssentia Corporation (TWSE: 6446), a Taiwan-based biopharmaceutical company, is expanding its global presence through new drug approvals, clinical trials and overseas investments, as it seeks to bring its Taiwan-developed innovative new drug to more international markets. Founded in Taiwan in 2003 by scientist Dr. Ko-Chung Lin (林國鐘), with a commitment to developing innovative treatments for patients worldwide, PharmaEssentia has developed integrated capabi...

دبي، الإمارات العربية المتحدة--(BUSINESS WIRE)--Dubai Culture: Dubai Ranks First Globally in Attracting New FDI Projects in Cultural and Creative Industries in 2025...

DALLAS--(BUSINESS WIRE)--LibertyStream Infrastructure Partners Inc. (TSXV: LIB | OTCQB: VLTLF | FSE: I2D) (“LibertyStream” or the “Company”) today provided an operational and commercial update. Since May 2026, LibertyStream has extracted and refined lithium carbonate at its Freedom Launchpad facility in Texas, which runs the full Freedom 1 process flow. A number of prospective end-user customers have validated this product or are completing their evaluation. Highlights Offtake discussions with...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust NYSE Arca Biotechnology UCITS ETF 15.10.2026 FBTU.LN IE00BL0L0H60 550,002.00 USD 18,077,945.88 32.869  ...

TAIPEI, Taiwan--(BUSINESS WIRE)--PharmaEssentia Corporation (TWSE: 6446), a Taiwan-based biopharmaceutical company, is expanding its global presence through new drug approvals, clinical trials and overseas investments, as it seeks to bring its Taiwan-developed innovative new drug to more international markets. Founded in Taiwan in 2003 by scientist Dr. Ko-Chung Lin (林國鐘), with a commitment to developing innovative treatments for patients worldwide, PharmaEssentia has developed integrated capabi...

TAIPEI, Taiwan--(BUSINESS WIRE)--PharmaEssentia Corporation (TWSE: 6446), a Taiwan-based biopharmaceutical company, is expanding its global presence through new drug approvals, clinical trials and overseas investments, as it seeks to bring its Taiwan-developed innovative new drug to more international markets. Founded in Taiwan in 2003 by scientist Dr. Ko-Chung Lin (林國鐘), with a commitment to developing innovative treatments for patients worldwide, PharmaEssentia has developed integrated capabi...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.   (c) Name o...

TAIPEI, Taiwan--(BUSINESS WIRE)--PharmaEssentia Corporation (TWSE: 6446), a Taiwan-based biopharmaceutical company, is expanding its global presence through new drug approvals, clinical trials and overseas investments, as it seeks to bring its Taiwan-developed innovative new drug to more international markets. Founded in Taiwan in 2003 by scientist Dr. Ko-Chung Lin (林國鐘), with a commitment to developing innovative treatments for patients worldwide, PharmaEssentia has developed integrated capabi...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Cloud Computing UCITS ETF 15.10.2026 CPQ IE00BFD2H405 6,225,002.00 USD 436,006,198.54   70.041  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust IPOX Europe Equity Opportunities UCITS ETF 15.10.2026 IPXE.IM IE00BFD26097 50,002.00 EUR 1,207,558.96 24.150  ...